Literature DB >> 20715927

Kaposi sarcoma (KS)-associated herpesvirus microRNA sequence analysis and KS risk in a European AIDS-KS case control study.

Vickie Marshall1, Elisa Martró, Nazzarena Labo, Alex Ray, Dian Wang, Georginia Mbisa, Rachel K Bagni, Natalia Volfovsky, Jordi Casabona, Denise Whitby.   

Abstract

BACKGROUND: We recently identified polymorphisms in Kaposi sarcoma-associated herpesvirus (KSHV)-encoded microRNA (miRNA) sequences from clinical subjects. Here, we examine whether any of these may contribute to KS risk in a European AIDS-KS case-control study.
METHODS: KSHV load in peripheral blood was determined by real-time quantitative polymerase chain reaction. Samples that had detectable viral loads were used to amplify the 2.8-kb miRNA encoding region plus a 646-bp fragment of the K12/T0.7 gene. Additionally, we characterized an 840-bp fragment of the K1 gene to determine KSHV subtypes.
RESULTS: KSHV DNA was detected in peripheral blood mononuclear cells of 49.6% of case patients and 6.8% of controls, and viral loads tended to be higher in case patients. Sequences from the miRNA-encoding regions were conserved overall, but distinct polymorphisms were detected, some of which occurred in primary miRNAs, pre-miRNAs, or mature miRNAs.
CONCLUSIONS: Patients with KS were more likely to have detectable viral loads than were controls without disease. Despite high conservation in KSHV miRNA-encoded sequences, polymorphisms were observed, including some that have been reported elsewhere. Some polymorphisms could affect mature miRNA processing and appear to be associated with KS risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20715927      PMCID: PMC2932837          DOI: 10.1086/656045

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  A quantification of human cells using an ERV-3 real time PCR assay.

Authors:  C C Yuan; W Miley; D Waters
Journal:  J Virol Methods       Date:  2001-02       Impact factor: 2.014

2.  Identification of virus-encoded microRNAs.

Authors:  Sébastien Pfeffer; Mihaela Zavolan; Friedrich A Grässer; Minchen Chien; James J Russo; Jingyue Ju; Bino John; Anton J Enright; Debora Marks; Chris Sander; Thomas Tuschl
Journal:  Science       Date:  2004-04-30       Impact factor: 47.728

3.  Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia.

Authors:  Dimitra Bourboulia; Diana Aldam; Dimitrios Lagos; Elizabeth Allen; Ian Williams; David Cornforth; Andrew Copas; Chris Boshoff
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

4.  Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy.

Authors:  John Wilkinson; Alethea Cope; Jas Gill; Dimitra Bourboulia; Peter Hayes; Nesrina Imami; Toru Kubo; Anne Marcelin; Vincent Calvez; Robin Weiss; Brian Gazzard; Chris Boshoff; Frances Gotch
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  Amino acid residue at position 13 in HLA-DR beta chain plays a critical role in the development of Kaposi's sarcoma in AIDS patients.

Authors:  Antoni Gayà; Anna Esteve; Jordi Casabona; Jeanette J McCarthy; Jaume Martorell; Thomas F Schulz; Denise Whitby
Journal:  AIDS       Date:  2004-01-23       Impact factor: 4.177

6.  Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes.

Authors:  Zhiqiang Qin; Patricia Kearney; Karlie Plaisance; Chris H Parsons
Journal:  J Leukoc Biol       Date:  2010-01       Impact factor: 4.962

7.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.

Authors:  Y Chang; E Cesarman; M S Pessin; F Lee; J Culpepper; D M Knowles; P S Moore
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

8.  Genotypic characterization of Kaposi's sarcoma-associated herpesvirus in asymptomatic infected subjects from isolated populations.

Authors:  Denise Whitby; Vickie A Marshall; Rachel K Bagni; Cheng Dian Wang; Christine J Gamache; Jose Rumbea Guzman; Michael Kron; Peter Ebbesen; Robert J Biggar
Journal:  J Gen Virol       Date:  2004-01       Impact factor: 3.891

9.  Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma.

Authors:  D Whitby; M R Howard; M Tenant-Flowers; N S Brink; A Copas; C Boshoff; T Hatzioannou; F E Suggett; D M Aldam; A S Denton
Journal:  Lancet       Date:  1995-09-23       Impact factor: 79.321

10.  Regulation of KSHV lytic switch protein expression by a virus-encoded microRNA: an evolutionary adaptation that fine-tunes lytic reactivation.

Authors:  Priya Bellare; Don Ganem
Journal:  Cell Host Microbe       Date:  2009-12-17       Impact factor: 21.023

View more
  19 in total

1.  MicroRNA expression profiles in Kaposi's sarcoma.

Authors:  Ana Maria Catrina Ene; Ioana Borze; Mohamed Guled; Mariana Costache; Gayle Leen; Maria Sajin; Elena Ionica; Aura Chitu; Sakari Knuutila
Journal:  Pathol Oncol Res       Date:  2013-09-13       Impact factor: 3.201

2.  Kaposi's sarcoma-associated herpesvirus microRNA single-nucleotide polymorphisms identified in clinical samples can affect microRNA processing, level of expression, and silencing activity.

Authors:  Soo-Jin Han; Vickie Marshall; Eugene Barsov; Octavio Quiñones; Alex Ray; Nazzarena Labo; Matthew Trivett; David Ott; Rolf Renne; Denise Whitby
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

3.  Rapid regression of Kaposi's sarcoma of the hard palate under therapy with boosted elvitegravir-containing fixdose antiretroviral combination therapy.

Authors:  Gundolf Schüttfort; Timo Wolf; Phillip de Leuw; Gerrit Kann; Maximilian Blume; Hans-Reinhard Brodt; Christoph Stephan
Journal:  Infection       Date:  2015-05-07       Impact factor: 3.553

4.  Kaposi's Sarcoma-associated Herpesvirus microRNA mutants modulate cancer hallmark phenotypic differences in human endothelial cells.

Authors:  Lauren A Gay; Daniel Stribling; Peter C Turner; Rolf Renne
Journal:  J Virol       Date:  2021-02-10       Impact factor: 5.103

5.  Sequence analysis of Kaposi sarcoma-associated herpesvirus (KSHV) microRNAs in patients with multicentric Castleman disease and KSHV-associated inflammatory cytokine syndrome.

Authors:  Alex Ray; Vickie Marshall; Thomas Uldrick; Robert Leighty; Nazzarena Labo; Kathy Wyvill; Karen Aleman; Mark N Polizzotto; Richard F Little; Robert Yarchoan; Denise Whitby
Journal:  J Infect Dis       Date:  2012-03-23       Impact factor: 5.226

Review 6.  KSHV microRNAs: Tricks of the Devil.

Authors:  Jie Qin; Wan Li; Shou-Jiang Gao; Chun Lu
Journal:  Trends Microbiol       Date:  2017-03-02       Impact factor: 17.079

7.  Kaposi's sarcoma-associated herpesvirus encodes a mimic of cellular miR-23.

Authors:  Mark Manzano; Priscilla Shamulailatpam; Archana N Raja; Eva Gottwein
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

Review 8.  Roles of Non-coding RNAs During Herpesvirus Infection.

Authors:  Meaghan H Hancock; Rebecca L Skalsky
Journal:  Curr Top Microbiol Immunol       Date:  2018       Impact factor: 4.291

Review 9.  Potential pitfalls in microRNA profiling.

Authors:  Pauline Chugh; Dirk P Dittmer
Journal:  Wiley Interdiscip Rev RNA       Date:  2012-05-07       Impact factor: 9.957

10.  MiR99a modulates MMP7 and MMP13 to regulate invasiveness of Kaposi's sarcoma.

Authors:  Jun Zhang; Shan Wang; Linya Lu; GuangHui Wei
Journal:  Tumour Biol       Date:  2014-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.